Following the company's investor day, Jefferies analyst Matthew Andrews says TherapeuticsMD remains a top small-cap pick for 2017. Multiple speakers discussed aspects of the vulvar and vaginal atrophy market and made a strong case for why TX-004 could be a differentiated drug and gain broad uptake, Andrews tells investors in a research note. The analyst believes TX-004 can take "meaningful share," even without a clean label with no boxed safety warnings, while TX-001 can become the new standard of care, especially in the compounding pharmacy. Andrews keeps a Buy rating on TherapeuticsMD with an $18 price target.